VETmAb Biosciences, Inc.

VETmAb Biosciences, Inc. develops monoclonal antibody (mAb) therapeutics for companion animals. The company addresses chronic diseases in dogs and cats by adapting human disease targets and advanced biologic solutions. This approach enables species-specific treatments, providing precise intervention in disease pathways and offering precision medicine for pets.

Founded in 2022 by Denise Bevers and Dr. Hangjun Zhan, VETmAb Biosciences addresses a critical need for advanced biologic therapies in animal health. Denise Bevers, Co-founder, President, and CEO, brings extensive experience from KindredBio. Dr. Zhan, Co-founder and Chair of the Scientific Advisory Committee, translates human mAb successes into effective pet treatments.

VETmAb Biosciences provides innovative therapeutic options for veterinarians treating companion animals. The company's vision is to improve pet quality of life and longevity through sophisticated biologic drugs. They are committed to advancing veterinary medicine by delivering targeted treatments enhancing health outcomes for dogs and cats.

High-Level Overview

VETmAb Biosciences, Inc. is a San Diego-based veterinary biopharmaceutical company founded in 2022, specializing in monoclonal antibody (mAb) therapies for dogs and cats to treat chronic and debilitating diseases.[1][2][3][5] The company develops caninized (dog-specific) and felinized (cat-specific) antibodies, leveraging human-validated targets to address conditions with limited or suboptimal treatments, serving veterinarians and pet owners in the animal health industry.[3][4][5] With $2.58M raised, including a $580K round about a year ago, and a small team of three employees, VETmAb shows early momentum through its experienced leadership and recognition as a 2023 CONNECT San Diego Cool Company.[1][2]

Origin Story

VETmAb Biosciences emerged in 2022 when co-founder and CEO Denise Bevers, a 35-year life sciences veteran and former co-founder of KindredBio (a veterinary biotech that went public in 2013 and sold to Elanco Animal Health), reconnected with ex-KindredBio colleagues CSO Hangjun Zhan and CEO Richard Chin.[2][3] While serving as COO at DTxPharma, Bevers identified an opportunity to apply advanced mAb and bispecific antibody technologies to pets at affordable price points, building on extensive human research to de-risk development.[2][3] This founding team, with proven success in veterinary biotech including FDA approvals from KindredBio, launched VETmAb to pioneer sophisticated therapeutics for companion animals, marking their second venture together.[3][5]

Core Differentiators

• Proven Founding Team: Composed of KindredBio alumni with decades of experience in veterinary biotech, including world-renowned protein engineers, capital-efficient drug developers, and executives with successful exits, enabling rapid progress and deep veterinary relationships.[2][3][5]
• Species-Specific mAb Technology: Develops caninized/felinized monoclonal and bispecific antibodies using proprietary processes like antigen design, high-affinity screening, stability assessment, and Fc modulation for optimal efficacy, safety, and manufacturability in dogs and cats.[3][4]
• De-Risked Approach: Leverages hundreds of millions in prior human research on validated targets, reducing technical and financial risks while targeting unmet needs in chronic diseases like atopic dermatitis, unlike traditional small-molecule drugs.[2][4][5]
• Veterinarian Focus: Prioritizes affordable, innovative therapies for modern practices, with upcoming clinical trials inviting vet clinics, backed by strong industry networks.[2][4][5]

Role in the Broader Tech Landscape

VETmAb rides the wave of veterinary biotech innovation, mirroring human medicine's mAb revolution (e.g., for cancer and autoimmune diseases) to address parallel pet conditions amid rising pet humanization and spending on premium care.[3][5] Timing aligns with successes like Zoetis (Pfizer's vet spinout), which created markets for pet dermatology drugs, and growing demand for biologics as pet ownership surges post-pandemic.[2] Favorable market forces include regulatory precedents from KindredBio's FDA approvals and investor interest in animal health, where VETmAb's de-risked model opens new opportunities for hard-to-treat diseases lacking approved therapies.[1][2][5] By bringing human-grade tech to vets, it influences the ecosystem, potentially accelerating adoption of biologics and inspiring more pet-focused biopharma startups.[3][4]

Quick Take & Future Outlook

VETmAb is poised for clinical trial launches and partnerships, building on its $2.58M funding and CONNECT backing to advance lead candidates in chronic pet diseases.[1][2][4] Trends like AI-accelerated antibody discovery, expanding vet biologics markets, and investor focus on animal health will propel growth, with the team's track record suggesting potential FDA paths and acquisitions akin to KindredBio.[2][3] Its influence may evolve by establishing mAbs as standard vet care, transforming pet health outcomes and validating the veterinary biotech space for broader investment. This positions VETmAb as a leader in bridging human and animal therapeutics.